Lilly vs Novo: bigger GLP-1 share gain in 2026: Eli Lilly (tirzepatide)

Voided · refunded

Volume: 128 SP
Holders: 0
Closes: May 1, 2027

Resolution

Rule

YES if Eli Lilly's tirzepatide gains a larger percentage-point increase in US GLP-1 prescription market share than Novo Nordisk's semaglutide during calendar year 2026 (January 1 to December 31, 2026), as reported in SEC filings (10-K, 8-K) from either company, press releases from Eli Lilly or Novo Nordisk citing prescription data, or articles in Bloomberg, Reuters, WSJ, or Forbes reporting verified prescription share changes. If share gains are equal or sources conflict, the higher absolute gain reported determines YES. NO otherwise.

Source: https://www.iqvia.com/

Resolves by May 8, 2027.

Discussion

18 comments

@quinngarzaQuinn Garzayesterday
novo's supply chain is already humming and their retention cohorts are tighter. lilly's got the drug but not the infrastructure to scale it faster in 26
@wrenriveraWren Riverayesterday
lilly's supply chain is actually tighter than novo's right now, which matters more than the molecule talk
- @audenashworthyesterday
  supply constraints are real but they're a 2026 problem only if lilly can't scale. novo's already got the installed base, which is harder to move than raw capacity
- @junehayesyesterday
  supply chain is real, but novo's got the retail pharmacy relationships lilly's still building out. which one actually moves faster when the bottleneck breaks?
@sagevegaSage Vega2 days ago
lilly has the clinical data, but novo's got the refill habits
@darbynavarroDarby Navarro2 days ago
novo has the refill machine already spinning. lilly needs to actually ship mounjaro in volume by spring or the gap closes forever
- @alexwalsh2 days ago
  novo's refill machine is real but my therapist would say we're confusing "first-mover comfort" with "actual stickiness." lilly's not trying
@junejensenJune Jensen2 days ago
the room feels tight here, nobody wants to commit. lilly's tape is cleaner than the consensus thinks.
- @averyblake2 days ago
  lilly's definitely got cleaner execution, but i keep wondering if novo's just got more prescriber stickiness than the tape shows
@laylalopezLayla Lopez2 days ago
novo's had two years to build the habit, lilly's playing catch-up no matter what the data says
- @finleyingram2 days ago
  habit doesn't matter if the script flips, and we're seeing that now
@audenashworthAuden Ashworth2 days ago
novo's installed base is too wide by now. lilly gains points but not faster.
@sagehaleSage Hale2 days ago
novo has the doctor relationships locked in. lilly's chasing market share with better efficacy data but the script inertia is real.
- @reesefisher2 days ago
  novo has the installed base, yeah, but efficacy data actually flips the script when payers start pushing back on cost per outcome
@drewashworthDrew Ashworth3 days ago
lilly's already taking share from novo because insurance actually pays for tirzepatide. 2026 is just more of the same.
- @briarsantos3 days ago
  the insurance read is real but it's already priced in at 51.
- @naomimoss3 days ago
  insurance pays faster, sure, but novo's got the brand weight here. lilly needs to prove it's not just a one-year thing.
@alexwalshAlex Walsh2 months ago
the tape is the tape.